ankyrin repeat and SOCS box containing 16Genealiases: []
Q-omics provides the consensus-scored ASB16 profile across patient tissues and cancer cell-line models. ASB16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ASB16 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ASB16 RNA expression shows 20,449 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, LIHC, and UVM as cancer lineages where ASB16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB16 survival associations across molecular data types. ASB16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB16 RNA expression–survival associations across cancer types. High ASB16 expression shows unfavorable associations in UVM, LGG and MESO, but favorable associations in UCS, BLCA and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ASB16 RNA expression.
This table summarizes ASB16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB16 shows lower tumor expression in KIRC, THCA, BLCA and KIRP and higher tumor expression in LIHC and KICH. The LIHC box plot shows higher ASB16 RNA expression in tumor versus normal tissue (log2 FC = +0.947, t-test p < 0.001).
This table shows molecular features associated with ASB16 in patient tissues and cancer cell lines. In patient samples, ASB16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
